Andrew B. Coxhead Net Worth

The estimated Net Worth of Andrew B. Coxhead is at least $4.31 Milion dollars as of 1 June 2015. Mr Coxhead owns over 5,000 units of Covetrus stock worth over $1,917,625 and over the last 17 years he sold CVET stock worth over $2,394,615.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr Coxhead CVET stock SEC Form 4 insiders trading

Mr has made over 10 trades of the Covetrus stock since 2010, according to the Form 4 filled with the SEC. Most recently he sold 5,000 units of CVET stock worth $95,400 on 1 June 2015.

The largest trade he's ever made was selling 15,000 units of Covetrus stock on 17 March 2014 worth over $277,500. On average, Mr trades about 2,015 units every 30 days since 2008. As of 1 June 2015 he still owns at least 91,359 units of Covetrus stock.

You can see the complete history of Mr Coxhead stock trades at the bottom of the page.

Mr. Andrew B. Coxhead biography

Andrew B. Coxhead is the VP, Corp. Controller & Chief Accounting Officer at Covetrus.

How old is Mr Coxhead?

Mr Coxhead is 52, he's been the VP a Corp. Controller & Chief Accounting Officer of Covetrus since . There are 15 older and 11 younger executives at Covetrus. The oldest executive at Covetrus, Inc. is Philip Laskawy, 78, who is the Independent Chairman of the Board.

What's Mr Coxhead's mailing address?

Andrew's mailing address filed with the SEC is 7, Custom House Street, India Street, Portland, Cumberland County, Maine, 04101, United States.

Insiders trading at Covetrus

Over the last 5 years, insiders at Covetrus have traded over $10,243,394 worth of Covetrus stock and bought 11,744 units worth $216,180 . The most active insiders traders include Steven Paladino, Benjamin Wolin a Philip A Laskawy. On average, Covetrus executives and independent directors trade stock every 10 days with the average trade being worth of $268,798. The most recent stock trade was executed by Rebecca Ann Kidd on 1 October 2022, trading 1,232 units of CVET stock currently worth $25,860.

What does Covetrus do?

Covetrus, Inc., together with its subsidiaries, operates as an animal-health technology and services company. It engages in the sale of animal-health consumable products, including proprietary and Covetrus branded products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, parasiticides, and vitamins and supplements to wholesale and retail customers. The company also offers value-added solutions that include, inventory management and e-commerce, as well as continuing education services for practitioners. In addition, it provides practice management software systems for veterinary practitioners and animal-health clinics, client communication services, reminders, data backup services, and hardware sales and support services. Further, the company engages in the distribution of finished goods pharmacy and specialty pharmaceutical compounding products, as well as shipping, manufacturer incentives, service fees, and data integration and support services. It serves animal-health and veterinary practices, and clinics in the companion-animal and equine markets primarily in North America, Europe, and the Asia Pacific. The company was formerly known as HS Spinco, Inc. Covetrus, Inc. was incorporated in 2018 and is headquartered in Portland, Maine.

Complete history of Mr Coxhead stock trades at R.R. Donnelley & Sons, R.R. Donnelley & Sons Co a Covetrus

Covetrus executives and stock owners

Covetrus executives and other stock owners filed with the SEC include:

• Benjamin Wolin,
  President, Chief Executive Officer, Director
• Dustin Finer,
  Chief Administrative Officer
• Georgina Wraight,
  Executive Vice President, President - Global Technology Solutions
• Benjamin Wolin,
  CEO, Pres & Director
• Georgina Wraight,
  Exec. VP & Pres of Global Technology Solutions
• Matthew J. Foulston,
  Exec. VP & Global CFO
• Philip Laskawy,
  Independent Chairman of the Board
• Dustin k. Finer,
  Chief Admin. Officer
• Sandra Helton,
  Independent Director
• Ravi Sachdev,
  Independent Director
• Edward McNamara,
  Independent Director
• Mark Manoff,
  Independent Director
• Deborah Ellinger,
  Independent Director
• Steven Paladino,
  Director
• Nicholas Jansen,
  Vice President of Investor Relations
• Sandra Peterson,
  Director
• Arman Samani,
  Chief Product Officer
• Steve Palmucci,
  Global Chief Information Officer
• Laura Phillips,
  Chief Accounting Officer, Vice President, Global Controller
• Erin Brennan,
  Senior Vice President, General Counsel, Secretary
• Anthony Providenti,
  Executive Vice President, Corporate Development
• Timothy Ludlow,
  Executive Vice President, Chief Transformation Officer
• David Hinton,
  Executive Vice President, President - APAC and Emerging Marke
• Michael Ellis,
  Executive Vice President, President - Europe and North America
• Matthew Malenfant,
  President, Customer Operations - North America
• Matthew Foulston,
  Global Chief Financial Officer
• Russell Cooke,
  Sr. VP & Operational CFO
• Ditte Marstrand Wulf,
  Global Chief HR Officer
• Kini Schoop,
  Director of PR
• Andrew B. Coxhead,
  VP, Corp. Controller & Chief Accounting Officer
• Bekki Kidd,
  Head of Operations & Operational Excellence
• Kiní Schoop,
  Director of PR
• Jamey S. Seely,
  Gen. Counsel & Corp. Sec.
• Paul R. Fonteyne,
  Director
• Andrew B. Coxhead,
  See Remarks
• Benjamin Shaw,
  Chief Executive Officer
• Investment Associates Ix, L...,
  
• Christine T Komola,
  See Remarks
• Sharon L Wienbar,
  Director
• Jamey S Seely,
  General Counsel and Secretary
• David Christopher Dollar,
  See Remarks
• Rebecca Ann Kidd,
  Head of Global Operations